Book Synopsis GLYCAEMIC VARIABILITY AND TIME IN RANGE IN TYPE 1 DIABETES PATIENTS ON REAL TIME CONTINUOUS GLUCOSE MONITORING AND INSULIN INJECTIONS VERSUS SENSOR-AUGMENTED INSULIN PUMP THERAPY. by :
Download or read book GLYCAEMIC VARIABILITY AND TIME IN RANGE IN TYPE 1 DIABETES PATIENTS ON REAL TIME CONTINUOUS GLUCOSE MONITORING AND INSULIN INJECTIONS VERSUS SENSOR-AUGMENTED INSULIN PUMP THERAPY. written by and published by . This book was released on 2017 with total page pages. Available in PDF, EPUB and Kindle. Book excerpt: Background and aims. The aim of the study was to compare glycaemic variability and time in different glycaemic ranges in patients with type 1 (T1DM) using real time continuous glucose monitoring (CGM) and multiple daily insulin injections (MDI) versus the patients using sensor-augmented pump therapy (SAP).Material and Methods. All the T1DM patients using real time CGM in a single center were evaluated in a cross-sectional study. Fourteen days of data from CGM and/or pump downloads were analysed. Different glycaemic variability measures were obtained. Percentage of TIR (70-180 mg/dl), time 54 mg/dl, 70 mg/dl, 180 mg/dl, 250 mg/dl and >300 mg/dl were calculated. A comparison between the group on MDI (CGM-MDI) and the group on SAP was performed.Results. 180 patients were included. No differences between the CGM-MDI group (n=70) and the SAP group (n=110) were found in age (42u00b114 vs 40u00b19.2 years, p=0.4), diabetes duration (20u00b112 vs 23u00b111 years, p=0.2), or baseline HbA1c before CGM (7.4u00b11.1% vs 7.4u00b10.8%, p=0.9). In the SAP group, female sex was more prevalent (63% vs 36%, p=0.001) and median duration of CGM was longer (25 [12-40] vs 11 [4-28] months, p=0.001). 87% (n=96) of the patients in the SAP group used low-glucose or predictive low-glucose suspend functions. Differences between both groups are shown in Table 1. Conclusion. Similar outcomes regarding glycaemic variability and time in normo- and hyperglycaemic range can be achieved with real time CGM and multiple daily insulin injections and with sensor-augmented pump. Sensor-augmented pump therapy provides greater protection against hypoglycaemia.